IP Library › Granted Patent US 8,257,706
Granted Patent B2
US 8,257,706 · App. 12/438,604 · Granted Sep 4, 2012

CD30 binding agents and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,257,706
App. No.
12/438,604
Granted
Sep 4, 2012
Kind
B2
Abstract

This invention relates to CD30 binding agents and methods of using such binding agents for treating disease characterized by expression of CD30 antigen.

Claims (26)

1. An isolated CD30 binding agent that specifically binds to human CD30, comprising:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:19, optionally comprising an amino acid substitution at position 71, position 91, or both positions 71 and 91, wherein the position is numbered according to the Kabat numbering system; and

a light chain variable region comprising the amino acid sequence of SEQ ID NO:26, optionally comprising an amino acid substitution at position 25, position 33, or both positions 25 and 33, wherein the position is numbered according to the Kabat numbering system.

2. The CD30 binding agent of claim 1 , wherein the CD30binding agent is conjugated to a cytotoxic agent.

3. The CD30 binding agent of claim 2 , wherein the cytotoxic agent is auristatin E, MMAE or MMAF.

4. The CD30 binding agent of claim 2 , wherein the cytotoxic agent is a chemotherapeutic agent.

5. The CD30 binding agent of claim 4 , wherein the chemotherapeutic agent is MMAE.

6. The CD30 binding agent of claim 2 , wherein the CD30 binding agent comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:19 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:26.

7. The CD30 binding agent of claim 1 , wherein the optional substitution at position 71 of the amino acid sequence of SEQ ID NO:19 is substitution of a valine residue in place of the arginine residue, the optional substitution at position 91 of the amino acid sequence of SEQ ID NO:19 is substitution of a phenylalanine residue in place of the tyrosine residue, the optional substitution at position 25 of the amino acid sequence of SEQ ID NO:26 is substitution of a serine residue in place of the alanine residue, and the optional substitution at position 33 of the amino acid sequence of SEQ ID NO:26 is substitution of a leucine residue in place of the methionine residue.

8. The CD30 binding agent of claim 7 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:19 having a valine residue in place of the arginine residue at position 71 and a phenylalanine residue in place of the tyrosine residue at position 91.

9. The CD30 binding agent of claim 7 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:19 having a phenylalanine residue in place of the tyrosine residue at position 91.

10. The CD30 binding agent of claim 7 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:19 having a valine residue in place of the arginine residue at position 71.

11. The CD30 binding agent of claim 7 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:26 having a serine residue in place of the alanine residue at position 25.

12. The CD30 binding agent of claim 7 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:26 having a leucine residue in place of the methionine residue at position 33.

13. The CD30 binding agent of claim 7 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:26 having a serine residue in place of the alanine residue at position 25 and having a leucine residue in place of the methionine residue at position 33.

14. The CD30 binding agent of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID:19.

15. The CD30 binding agent of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:26.

16. A pharmaceutical composition comprising:

(i) the CD30 binding agent of claim 1 ; and

(ii) a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 , wherein the antibody is conjugated to a cytotoxic, cytostatic or immunosuppressive agent.

18. The pharmaceutical composition of claim 16 , wherein the CD30 binding agent comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:19 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:26.

19. An isolated CD30 binding agent that specifically binds to human CD30, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:19 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:26.

20. The CD30 binding agent of claim 19 , further comprising a human IgG constant region joined to the heavy chain variable region and a human light chain constant domain joined to the light chain variable region.

21. The CD30 binding agent of claim 20 , wherein the human IgG constant domain is human IgG1, and the human light chain constant domain is human κ(kappa).

22. The CD30 binding agent of claim 21 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:22 and the light chain comprises the amino acid sequence of SEQ ID NO:29.

Assignments (1)
CHANGE OF NAME Recorded Nov 12, 2020
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 054392/0656 →